You are using an outdated browser. We suggest you update your browser for a better experience.
Click here
for update.
Close this notification.
Skip to main content
Skip to search
CCO
Cancer Care Ontario
Ontario Renal Network
EN
FR
Recently Viewed
Cancer Care Ontario
Open Navigation
Close Navigation
Home
Types of Cancer
Cancer Treatments
Get Checked for Cancer
Find Services
Indigenous
Ontario Cancer Plan
COVID-19
Drug Formulary
Drugs
Regimens
Funding & Reimbursement
Side Effects
Drug Safety & Information
Pre-Printed Orders
What’s New
Guidelines & Advice
Browse Guidelines
Types of Cancer
Modality of Care
Cancer Continuum
Most Popular Documents
What’s New in Guidelines & Advice
About Guidelines
Toolkits
Education & Events
Managing Symptoms
COVID-19 Resources
Pathway Maps
Browse Pathway Maps
Bladder Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Esophageal Cancer
Lung Cancer
Oropharyngeal Cancer
Ovarian Cancer
Prostate Cancer
Skin Cancer
Soft Tissue Sarcoma
Thyroid Cancer
Cervical Lymphadenopathy in Adults Pathway Map
Hepatocellular Cancer Pathway Map
Data & Research
Accessing Data
View Data
Submitting Data
Our Research
Funding Opportunities
Open Search
Close Search
Open Navigation
Close Navigation
All
Drug Formulary
Guidelines and Advice
Data
Cancer Care Ontario
General Cancer Info
Pathway Maps
Sort by
Most Relevant
Letter (A-Z)
Most Recent
You are here
Search
You may filter this list by entering a keyword to the right
Refine Your Results
5 Results
Regimen
LIPOCYTADAUN(CONS)
Cancer Type:
Hematologic
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Curative, Palliative
Funding:
New Drug Funding Program
Liposomal Daunorubicin and Liposomal Cytarabine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
liposomal DAUNOrubicin / liposomal cytarabine
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023
Regimen
LOMU+BEVA
Cancer Type:
Central Nervous System
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Palliative
Funding:
ODB - General Benefit
lomustine
New Drug Funding Program
Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
lomustine
,
bevacizumab
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Regimen
LENV+PEMB
Cancer Type:
Gynecologic,
Endometrial
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Palliative
Funding:
Exceptional Access Program
lenvatinib - In Combination with Pembrolizumab for Advanced Endometrial Cancer
New Drug Funding Program
Pembrolizumab - In Combination with Lenvatinib for Advanced Endometrial Cancer
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
lenvatinib
,
pembrolizumab
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Drug
liposomal DAUNOrubicin / liposomal cytarabine
Other Name(s): Vyxeos®
Quick Link(s):
Drug Monograph
,
Patient Info Sheet
Dec 2023
Regimen
LENV+PEMB
Cancer Type:
Genitourinary,
Renal cell / Kidney
Show More
Show more tags
, Show Less
Show fewer tags
Intent:
Palliative
Funding:
Exceptional Access Program
lenvatinib - In Combination with Pembrolizumab for First-Line Advanced or Metastatic Renal Cell Carcinoma
New Drug Funding Program
Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma
Show More
Show more tags
, Show Less
Show fewer tags
Drugs Used:
lenvatinib
,
pembrolizumab
...
Show more tags
, Collapse
Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023